Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

• Advanced Solid Tumors
• Non Small Cell Lung Cancer

• Drug: sunitinib
  
  25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
• Drug: docetaxel
  
  60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion

Inclusion Criteria:

Advanced solid tumor malignancy ECOG 0 or 1

Exclusion Criteria:

Prior treatment with with high-dose chemotherapy requiring stem cell rescue Prior irradiation to ?25% of the bone marrow (e.g. whole pelvis=25%) Patients with centrally located lung lesions unless recently treated with radiotherapy